According to the new research, published in the International Journal of Immunopharmacology, Zadaxin may be most effective when administered between chemotherapy and treatment with cytokine drugs such as interferon and interleukin-2.
Dr Enrico Garaci, of the University of Rome, Italy, reports that Zadaxin reduces the hematological toxicity of cytotoxic drugs.
|Zadaxin potentiates the action of cytokines and also reduces the hematological toxicity of cytotoxic drugs.
|International Journal of Immunopharmacology|
It also potentiates the action of cytokines, according to his review of research into the drug.
Zadaxin, developed by Sciclone Pharmaceuticals, of San Mateo, California, USA, is undergoing Phase II trials for liver cancer in the USA, and is approved for sale in 21 countries for the treatment of hepatitis B and C. Phase II and Phase III clinical studies of its effectiveness in hepatitis treatment are under way in the USA, Europe, and Japan.
Dr Garaci said, "This schedule of treatment seems the most efficient in that it allows each agent to exert its specific function through a metabolic pathway on which the successive agent may properly intervene."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com